title: P16-immunostaining pattern as a predictive marker of lymph node metastasis and recurrence in early uterine cervical cancer.
abstract: OBJECTIVE
  We investigated the relationship between P16-immunostaining patterns and clinicopathological factors in early uterine cervix cancers and assessed whether P16-immunostaining patterns predict the prognosis of the patients with early uterine cervix cancers.
  
  
  METHODS
  Twenty-nine early squamous cell carcinoma (SCC) specimens of the uterus were examined using immunohistochemistry for P16 expression. The P16-immunostaining pattern was classified into two groups: the homogeneous type and the heterogeneous type. P16-immunostaining patterns were evaluated in different parts of the carcinoma in situ (CIS): the center of the tumor and the front interface of the infiltrating tumor.
  
  
  RESULTS
  All specimens were of the homogeneous type in CIS. The P16-immunostaining pattern was significantly of the heterogeneous type in the front interface of the infiltrating tumor with lymphatic invasion, vascular invasion, lymph node metastasis, and recurrence. Regarding the P16-immunostaining patterns in the front interface of the infiltrating tumor, the patients with the heterogeneous type showed a significantly worse prognosis than the patients with the homogeneous type.
  
  
  CONCLUSIONS
  The prognosis of patients with early uterine cervical SCC may be predicted by evaluating the P16-immunostaining pattern in the front interface of the infiltrating tumor.
authors.affiliation: Department of Obstetrics and Gynecology, Dokkyo University School of Medicine, Shimotsuga, Tochigi, Japan.
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Yamazaki
authors.forename: Shigeki
authors.initials: S
authors.lastname: Tomita
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Ichikawa
authors.forename: Yuko
authors.initials: Y
authors.lastname: Ono
authors.forename: Fujiyuki
authors.initials: F
authors.lastname: Inaba
authors.forename: Ichio
authors.initials: I
authors.lastname: Fukasawa
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Imai
authors.forename: Johji
authors.initials: J
authors.lastname: Imura
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Fukui
authors.forename: Takahiro
authors.initials: T
authors.lastname: Fujimori
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Inaba
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000401:mortality / Q000556:secondary; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000378:metabolism*; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D019941:Cyclin-Dependent Kinase Inhibitor p16